as well as a 2020 deal with Australian biotech oNKo-innate to find targets that boost NK cell activity against tumours. Along with the upfront payment, Dragonfly is in line for undisclosed opt-in ...

Investigators at Dana-Farber Cancer Institute are opening a new clinical trial to evaluate a novel type of immune cellular ...

Risk - "Early" is often a massive weakness Being in phase 1 studies makes for an important milestone, but without a lot of clear evidence about the activity and safety of these NK cell therapies ...

These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...

inhibits the anti-tumor activity of natural killer (NK) cells through its receptor. They also proposed a new immunotherapy strategy based on receptor antagonism. Their study was published in ...

The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation, which will build upon longstanding MD Anderson clinical and ...

Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...

Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated cell therapies for the treatment of cancer and autoimmune diseases, today ...